CNTA

NEUTRALM&A

Centessa Pharmaceuticals plc

2026-06-03

Price

$39.85

-0.13%

Score12.5Top Tier

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.8xvs 20d avg

Analysis

Centessa Pharmaceuticals' remarkably low volatility and tight price action are entirely driven by its pending $7.8 billion acquisition by Eli Lilly. The definitive agreement features a $38 per share cash base plus a $9 Contingent Value Right (CVR), pinning the stock near $39.85 as the market prices in the cash floor plus a partial probability of the CVR payout. Despite the broader market snapping its winning streak due to U.S.-Iran geopolitical stress, CNTA exhibits classic institutional absorption and merger arbitrage dynamics. This RISK_ON macro backdrop ensures liquidity remains robust for deal closures, perfectly explaining the QUIET_STORM and STEADY_CLIMB signals as the stock completely ignores macro noise.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable Thesis: CNTA is a pure merger arbitrage and CVR probability play; the current $39.85 price reflects the $38 cash offer plus a ~$1.85 premium for the $9 CVR [1.2.1].
Key Risk: Regulatory (FTC) pushback on Eli Lilly's neuroscience expansion or clinical failures in the OX2R agonist pipeline that would wipe out the CVR value.
What to Watch: Monitor antitrust clearance progress and any clinical updates on cleminorexton (ORX750) that could trigger the CVR milestones.

← Back to 2026-06-03 View Full CNTA History →Yahoo Finance &nearr;